Business Bites: Spectranetics and Volcano go shopping
This article was originally published in Clinica
Two cardiovascular device companies have made their first acquisitions of 2014: Spectranetics has agreed to buy balloon developer AngioScore for $230m upfront; while Volcano has inked a deal for peripheral arterial disease specialist AtheroMed for $115m plus milestones.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.